Cargando…

Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis

Objective  To compare the use of mirabegron with anticholinergics drugs for the treatment of overactive bladder (OB). Data Source  Systematic searches were conducted in EMBASE, PUBMED, Cochrane, and LILACS databases from inception to September 2021. We included RCTs, women with clinically proven OB...

Descripción completa

Detalles Bibliográficos
Autores principales: Sartori, Luisa Gracio Ferreira, Nunes, Bruno Monteiro, Farah, Daniela, Oliveira, Leticia Maria de, Novoa, Claudia Cristina Takano, Sartori, Marair Gracio Ferreira, Fonseca, Marcelo Cunio Machado
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Thieme Revinter Publicações Ltda. 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371066/
https://www.ncbi.nlm.nih.gov/pubmed/37494577
http://dx.doi.org/10.1055/s-0043-1770093
_version_ 1785078074581188608
author Sartori, Luisa Gracio Ferreira
Nunes, Bruno Monteiro
Farah, Daniela
Oliveira, Leticia Maria de
Novoa, Claudia Cristina Takano
Sartori, Marair Gracio Ferreira
Fonseca, Marcelo Cunio Machado
author_facet Sartori, Luisa Gracio Ferreira
Nunes, Bruno Monteiro
Farah, Daniela
Oliveira, Leticia Maria de
Novoa, Claudia Cristina Takano
Sartori, Marair Gracio Ferreira
Fonseca, Marcelo Cunio Machado
author_sort Sartori, Luisa Gracio Ferreira
collection PubMed
description Objective  To compare the use of mirabegron with anticholinergics drugs for the treatment of overactive bladder (OB). Data Source  Systematic searches were conducted in EMBASE, PUBMED, Cochrane, and LILACS databases from inception to September 2021. We included RCTs, women with clinically proven OB symptoms, studies that compared mirabegron to antimuscarinic drugs, and that evaluated the efficacy, safety or adherence. Data Collection  RevMan 5.4 was used to combine results across studies. We derived risk ratios (RRs) and mean differences with 95% CIs using a random-effects meta-analytic model. Cochrane Collaboration Tool and GRADE was applied for risk of bias and quality of the evidence. Data Synthesis  We included 14 studies with a total of 10,774 patients. Fewer total adverse events was reported in mirabegron group than in antimuscarinics group [RR 0.93 (0.89–0.98)]. The risk of gastrointestinal tract disorders and dry mouth were lower with mirabegron [RR 0,58 (0.48–0.68); 9375 patients; RR 0.44 (0.35–0.56), 9375 patients, respectively]. No difference was reported between mirabegron and antimuscarinics drugs for efficacy. The adherence to treatment was 87.7% in both groups [RR 0.99 (0.98–1.00)]. Conclusion  Mirabegron and antimuscarinics have comparable efficacy and adherence rates; however, mirabegron showed fewer total and isolated adverse events.
format Online
Article
Text
id pubmed-10371066
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Thieme Revinter Publicações Ltda.
record_format MEDLINE/PubMed
spelling pubmed-103710662023-07-27 Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis Sartori, Luisa Gracio Ferreira Nunes, Bruno Monteiro Farah, Daniela Oliveira, Leticia Maria de Novoa, Claudia Cristina Takano Sartori, Marair Gracio Ferreira Fonseca, Marcelo Cunio Machado Rev Bras Ginecol Obstet Objective  To compare the use of mirabegron with anticholinergics drugs for the treatment of overactive bladder (OB). Data Source  Systematic searches were conducted in EMBASE, PUBMED, Cochrane, and LILACS databases from inception to September 2021. We included RCTs, women with clinically proven OB symptoms, studies that compared mirabegron to antimuscarinic drugs, and that evaluated the efficacy, safety or adherence. Data Collection  RevMan 5.4 was used to combine results across studies. We derived risk ratios (RRs) and mean differences with 95% CIs using a random-effects meta-analytic model. Cochrane Collaboration Tool and GRADE was applied for risk of bias and quality of the evidence. Data Synthesis  We included 14 studies with a total of 10,774 patients. Fewer total adverse events was reported in mirabegron group than in antimuscarinics group [RR 0.93 (0.89–0.98)]. The risk of gastrointestinal tract disorders and dry mouth were lower with mirabegron [RR 0,58 (0.48–0.68); 9375 patients; RR 0.44 (0.35–0.56), 9375 patients, respectively]. No difference was reported between mirabegron and antimuscarinics drugs for efficacy. The adherence to treatment was 87.7% in both groups [RR 0.99 (0.98–1.00)]. Conclusion  Mirabegron and antimuscarinics have comparable efficacy and adherence rates; however, mirabegron showed fewer total and isolated adverse events. Thieme Revinter Publicações Ltda. 2023-07-21 /pmc/articles/PMC10371066/ /pubmed/37494577 http://dx.doi.org/10.1055/s-0043-1770093 Text en Federação Brasileira de Ginecologia e Obstetrícia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. ( https://creativecommons.org/licenses/by/4.0/ ) https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Sartori, Luisa Gracio Ferreira
Nunes, Bruno Monteiro
Farah, Daniela
Oliveira, Leticia Maria de
Novoa, Claudia Cristina Takano
Sartori, Marair Gracio Ferreira
Fonseca, Marcelo Cunio Machado
Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis
title Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis
title_full Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis
title_fullStr Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis
title_full_unstemmed Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis
title_short Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis
title_sort mirabegron and anticholinergics in the treatment of overactive bladder syndrome: a meta-analysis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371066/
https://www.ncbi.nlm.nih.gov/pubmed/37494577
http://dx.doi.org/10.1055/s-0043-1770093
work_keys_str_mv AT sartoriluisagracioferreira mirabegronandanticholinergicsinthetreatmentofoveractivebladdersyndromeametaanalysis
AT nunesbrunomonteiro mirabegronandanticholinergicsinthetreatmentofoveractivebladdersyndromeametaanalysis
AT farahdaniela mirabegronandanticholinergicsinthetreatmentofoveractivebladdersyndromeametaanalysis
AT oliveiraleticiamariade mirabegronandanticholinergicsinthetreatmentofoveractivebladdersyndromeametaanalysis
AT novoaclaudiacristinatakano mirabegronandanticholinergicsinthetreatmentofoveractivebladdersyndromeametaanalysis
AT sartorimarairgracioferreira mirabegronandanticholinergicsinthetreatmentofoveractivebladdersyndromeametaanalysis
AT fonsecamarcelocuniomachado mirabegronandanticholinergicsinthetreatmentofoveractivebladdersyndromeametaanalysis